Contribute Try STAT+ Today

Cutting-edge science and the development of groundbreaking and lifesaving drugs get a lot of attention, but the everyday practice of medicine is often more mundane: It doesn’t involve being CRISPR’d or having gene therapy delivered into your cells. The truth is that most people who are very sick and visit their doctor get treated with very ordinary and sometimes very old drugs.

But in recent years supplies of some of these critical standby medicines have become disrupted. The shortages have forced doctors to make hard treatment decisions. Drugs have to be rationed or, in the worst cases, patients who need care can be turned away.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Stick to medicine, doc, b/c you either are clueless about economics, and the HC supply chain OR you’re afraid to address the real root cause —-Gpos —for fear of reprisal from your ceo. Hc journos clueless too. Bad info drives out good, For the exhaustively documented facts visit

  • Merck uses just 1 of the available strains of BCG (TICE). There are several other strains that are more effective than TICE (TheraCys) which have been through clinical trials but are not longer produced. And there are others, such as the Tokyo-172 strain, that are currently in production but not available to the Western drug market.

    Tokyo-172 is not a new drug. It’s being used extensively in S.Korea, Taiwan & Japan. There’s no reason for the FDA to require new clinical trials to get this strain into the US market to relieve the current TICE shortage.

    Enough of blaming Merk for this shortage. In view of prior TICE BCG shortages, the medical field has not been adamant in demanding the FDA put an end to Merck’s monopoly. Alternative strains already in production must be approved for distribution in the US market now.

  • Hello I like your collum very much. I would like to tell you that the problem with cancer is only one “Greed, every body want to make money out the cancer patients.

    I know that at first hand. My sister passed from cancer of the mamma at ,36.
    The traditional treatments are basically the same for the last one hundred years, and they don’t work. The five years survival is only the time the cancer needs to come back and kill the patient.

    Doctors say that there is no cure for cancer. I believe that is the result of a one hundred years very profitable business. I will bet you money, that if the price of chemotherapy go down to the the price of a hot dog the big cancer companies will put all their efforts in finding the cure for this horrible sickness.

    Almost every day, they said they have a new cancer drug that will give the patient a few months more to live in horrible pain and poor quality of life. This new drug usually have a very high cost.

    We will have the cure for cancer in no time, when they see that there is not much profits in Chemotherapy.

    Also, I believe that a cancer patient must be allowed to use the treatments he wants.

    • I suppose if they raise the price, then another pharma will invest the $100 million to open their own production line, and Merck will lose its monopoly. Better solution is to designate a list of essential low-margin drugs and establish a regulatory framework as with your local electric company: price and reliability of supply is regulated, with price set to guarantee a designated rate of return. Ideally, big pharma should co-operate in jointly funding these “regulated utility’ facilities.

  • People should urge the FDA to approve new drugs in the pipeline to help patients with bladder cancer. Vicinium is one of them, being developed by Sesen Bio. I own their stock and hope that they can start producing the drug commercially sooner than later.

    • No conflict of interest here (sarcasm alert). Kind of makes the point that grasping for money means more than grasping for outcomes.

Comments are closed.